Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Prentki

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Nature Reviews. Drug Discovery|April 3, 2004
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndromeNeil Ruderman, Marc Prentki
The Journal of Clinical Investigation|July 11, 2006
Islet beta cell failure in type 2 diabetesMarc Prentki, Christopher J Nolan
Diabetes & Vascular Disease Research|February 17, 2019
Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shiftChristopher J Nolan, Marc Prentki
Trends in Endocrinology and Metabolism: TEM|September 9, 2008
The islet beta-cell: fuel responsive and vulnerableChristopher J Nolan, Marc Prentki
Endocrine Reviews|July 9, 2008
Glycerolipid metabolism and signaling in health and diseaseMarc Prentki, S R Murthy Madiraju
Molecular and Cellular Endocrinology|November 24, 2011
Glycerolipid/free fatty acid cycle and islet β-cell function in health, obesity and diabetesMarc Prentki, S R Murthy Madiraju
Lancet (London, England)|June 28, 2011
Type 2 diabetes across generations: from pathophysiology to prevention and managementChristopher J Nolan, Peter Damm, Marc Prentki
Diabetes|December 28, 2002
Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptorJean Buteau, Sylvain Foisy, Erik Joly, et al.
Molecular and Cellular Endocrinology|September 4, 2012
β-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic β INS832/13 cellsJason Talbot, Erik Joly, Marc Prentki, et al.
Biochimie|August 23, 2017
Glycerol-3-phosphate phosphatase/PGP: Role in intermediary metabolism and target for cardiometabolic diseasesElite Possik, S R Murthy Madiraju, Marc Prentki
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Nature Reviews. Drug Discovery|April 3, 2004
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndromeNeil Ruderman, Marc Prentki
The Journal of Clinical Investigation|July 11, 2006
Islet beta cell failure in type 2 diabetesMarc Prentki, Christopher J Nolan
Diabetes & Vascular Disease Research|February 17, 2019
Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shiftChristopher J Nolan, Marc Prentki
Trends in Endocrinology and Metabolism: TEM|September 9, 2008
The islet beta-cell: fuel responsive and vulnerableChristopher J Nolan, Marc Prentki
Endocrine Reviews|July 9, 2008
Glycerolipid metabolism and signaling in health and diseaseMarc Prentki, S R Murthy Madiraju
Molecular and Cellular Endocrinology|November 24, 2011
Glycerolipid/free fatty acid cycle and islet β-cell function in health, obesity and diabetesMarc Prentki, S R Murthy Madiraju
Lancet (London, England)|June 28, 2011
Type 2 diabetes across generations: from pathophysiology to prevention and managementChristopher J Nolan, Peter Damm, Marc Prentki
Diabetes|December 28, 2002
Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptorJean Buteau, Sylvain Foisy, Erik Joly, et al.
Molecular and Cellular Endocrinology|September 4, 2012
β-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic β INS832/13 cellsJason Talbot, Erik Joly, Marc Prentki, et al.
Biochimie|August 23, 2017
Glycerol-3-phosphate phosphatase/PGP: Role in intermediary metabolism and target for cardiometabolic diseasesElite Possik, S R Murthy Madiraju, Marc Prentki
Pageof 13